Cationic liposomes are used for the delivery of genetic materials such as various types of DNA and RNA. In order to capture more plasmid efficiently, the negative charge of pDNA is neutralized with positive charge of cationic lipids due to electrostatic interaction and deliver them into cells. So they are researched for use as delivery vectors in gene therapy.
Lipid Composition
DC-Chol: 50M DOPE:50M
Applications
Cancer research; Target delivery
Hydration Solution
Deionized RNAse-free Water
External Solution
Deionized RNAse-free Water
Storage
2°C - 8°C in dark (do not freeze)
Size
100 nm
Shelf Life
6 months
Quantity
5mL (available in lyophilized powder)
Dosage
Download
DataSheet
MSDS
FAQsPublished Data Customer ReviewsRelated Sections
What are the primary components and characteristics of DC-Chol:DOPE (50:50) liposomes?
DC-Chol:DOPE (50:50) liposomes consist of a mixture of DC-Cholesterol (DC-Chol) and Dioleoylphosphatidylethanolamine (DOPE) in a 1:1 molar ratio. This combination creates cationic liposomes that are particularly effective for DNA and RNA delivery due to their positive charge and fusogenic properties, facilitating efficient cellular uptake and endosomal escape.
How does PEGylation affect the performance of DC-Chol:DOPE liposomes in gene delivery?
PEGylation, the process of attaching polyethylene glycol (PEG) polymers to the surface of liposomes, significantly enhances the biocompatibility and serum stability of DC-Chol:DOPE liposomes. It reduces interactions with serum proteins and phagocytic cells, such as Kupffer cells in the liver, thus prolonging their circulation time and improving biodistribution. However, PEGylation may also reduce cellular interaction and uptake, necessitating a balance between enhanced circulation and efficient cellular delivery.
What factors influence the cytotoxicity of DC-Chol:DOPE liposomes?
Cytotoxicity levels of DC-Chol:DOPE liposomes vary depending on their formulation and concentration. Studies indicate that PEGylated versions tend to exhibit lower toxicity compared to their non-PEGylated counterparts. Moreover, reducing the concentration of the liposomes and adjusting the molar ratio of DC-Chol to DOPE can significantly mitigate cytotoxic effects, enhancing cell viability.
How does the DNA binding affinity of DC-Chol:DOPE liposomes impact gene delivery?
The DNA binding affinity of DC-Chol:DOPE liposomes is crucial for successful gene delivery. This affinity ensures the formation of stable complexes between the liposomes and the DNA, which is necessary for protecting the genetic material from degradation and facilitating its cellular uptake and subsequent expression within the target cells.
What are the best practices for using DC-Chol:DOPE liposomes in experimental setups?
To achieve optimal results with DC-Chol:DOPE liposomes, it's important to carefully titrate the liposome-to-nucleic acid ratio, monitor the concentration used, and consider the application of PEGylation or ligand targeting based on the experimental goals. Preliminary in vitro experiments to assess transfection efficiency, cytotoxicity, and target specificity are recommended before proceeding to in vivo studies.
One-dimensional 10% polyacrylamide gel electrophoresis obtained by analyzing four samples of plasma proteins desorbed from cationic liposomes
The research provides an in-depth analysis of plasma protein adsorption onto DC-Chol:DOPE (50:50) liposomes, highlighting its significance in gene therapy and the design of drug carriers. The study meticulously identifies fifty-eight human plasma proteins adsorbed onto the liposomes through an integrated method combining protein separation by one-dimensional polyacrylamide gel electrophoresis and HPLC-Chip technology coupled to a high-resolution mass spectrometer. This approach is groundbreaking for its efficiency in characterizing the "protein corona" formed around cationic liposomes when they interact with human plasma. The findings offer invaluable insights into the interactions between liposomes and plasma proteins, underscoring the potential of DC-Chol:DOPE liposomes in the targeted delivery of genetic material. Such knowledge is pivotal for the advancement of non-viral gene delivery systems, aiming to overcome limitations posed by viral vectors in gene therapy. The research opens avenues for designing more effective colloidal drug carriers and biocompatible surfaces for medical devices, leveraging the understanding of liposome-protein interactions to enhance the in vivo distribution and functionality of nanocarriers.
Capriotti, A. L., Caracciolo, G., et al. Analysis of plasma protein adsorption onto DC-Chol-DOPE cationic liposomes by HPLC-CHIP coupled to a Q-TOF mass spectrometer. Analytical and bioanalytical chemistry. 2010, 398: 2895-2903.
Optimized for Precision
The precision of drug delivery observed with DC-Chol:DOPE liposomes from Creative Biolabs is unmatched. Their formulation ensures targeted release, enhancing the effectiveness of therapeutics in cellular studies.
Benchmark for Quality
Creative Biolabs sets the benchmark for liposome quality. Their DC-Chol:DOPE product exhibits exceptional consistency and reliability, crucial for reproducible results in our pharmacological research.
Advanced Formulation
The advanced formulation of DC-Chol:DOPE (50:50) liposomes facilitates unparalleled nucleic acid delivery. This has been a game-changer in our RNA-based therapies development, showcasing their superiority over traditional vectors.
Robust and Versatile
The robustness and versatility of DC-Chol:DOPE liposomes make them ideal for a wide range of biomedical applications. Their performance in delivering both hydrophilic and hydrophobic compounds is truly remarkable.
Cutting-edge Research Enabled
Thanks to the high-quality DC-Chol:DOPE liposomes from Creative Biolabs, cutting-edge research in targeted gene therapy has been significantly advanced. Their product's reliability and efficiency in gene silencing experiments are exceptional.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use